Background and context
Who wrote it and where it appeared
Alhazmi is at Jazan University Hospital in Saudi Arabia and at University College Dublin. Le Roux is at University College Dublin and Ulster University. PubMed lists the article in a supplement issue of the journal (volume 28, supplement 5, pages 42 to 50) and shows no company affiliation for either author.
Funding and disclosures
The full text says the article was commissioned by the editor as part of a themed issue made possible by funding from Zealand Pharmaceutical, and that the sponsor was not disclosed to the authors before publication. The authors report no funding of their own. Alhazmi declares no conflicts. Le Roux reports personal fees from several drugmakers, including Eli Lilly and Novo Nordisk, and advisory board or speaker roles at others. The article has a named handling editor and links to a peer review history.
How the literature was gathered
The authors searched PubMed/MEDLINE, ClinicalTrials.gov, Google Scholar, company press releases, investor reports and major congress abstracts. They covered amylin-based therapies that were approved or in human development for obesity as of 30 April 2026.
Other drugs in the review
Besides eloralintide, the abstract names pramlintide, the first approved amylin analogue, which it describes as limited by modest efficacy and frequent dosing. It also names the long-acting agents cagrilintide, petrelintide, MET-233i, ABBV-295 and AZD6234, and combination approaches such as cagrilintide with semaglutide and zenagamtide.
Alhazmi A, le Roux CW, Diabetes, Obesity and Metabolism, 2026, volume 28, supplement 5, via PubMed (PMID 42452898). DOI 10.1111/dom.71074.